EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6HN: EVEREST MED.LTD DL-0001

10 Feb 2026
LAST:

4.160

CHANGE:
 0.02		OPEN:
4.160		HIGH:
4.160		ASK:
0.000		VOLUME:
472
CHG(%):
0.48		PREV:
4.140		LOW:
4.160		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
10 Feb 264.1604.1604.1604.160472
09 Feb 264.1404.1404.1404.140472
06 Feb 264.2004.2004.2004.200472
05 Feb 264.1404.1404.1404.140472
04 Feb 264.0204.0204.0204.020472
03 Feb 263.9403.9403.9403.9400
02 Feb 263.9403.9403.9403.9400
30 Jan 264.0804.0804.0804.080472
29 Jan 264.1604.1604.1604.160472
28 Jan 264.2404.2404.2404.240472

PROFILE

Name:EVEREST MED.LTD DL-0001
About:Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton's tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
Sector:Healthcare
Industry:Biotechnology
Address:CITIC Pacific Plaza, 16/F, Shanghai, China, 200041
Website:https://www.everestmedicines.com
ISIN:KYG3224E1061

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-1.52 
Price to Sales:2.09 
Price to Book:3.42 
Profit Margin:-0.77 
Operating Margin:-0.62 
Return on Assets:-0.21 
Return on Equity:-0.26 
Revenue:102.96M 
Shares:350.63M 
Market Cap:1.459B 

TECHNICAL INDICATORS

MA5:4.130.7%
MA10:4.101.4%
MA20:4.170.2%
MA50:4.497.9%
MA100:5.0320.8%
MA200:5.7237.4%
STO9:84.62 
STO14:40.74
RSI14:54.32
WPR14:-59.26
MTM14:0.04
ROC14:0.01 
ATR:0.12 
Week High:4.201.0%
Week Low:3.945.6%
Month High:4.487.7%
Month Low:3.9437.4%
Year High:8.2397.8%
Year Low:3.945.6%
Volatility:84.30